APA
Click to copy
Spratt, J., Dias, J. M., Kolonelou, C., Kiriako, G., Engström, E., Petrova, E., … Teixeira, A. I. (2023). Multivalent insulin receptor activation using insulin–DNA origami nanostructures. Nature Nanotechnology.
Chicago/Turabian
Click to copy
Spratt, Joel, José M. Dias, Christina Kolonelou, Georges Kiriako, Enya Engström, Ekaterina Petrova, Christos Karampelias, et al. “Multivalent Insulin Receptor Activation Using Insulin–DNA Origami Nanostructures.” Nature Nanotechnology (2023).
MLA
Click to copy
Spratt, Joel, et al. “Multivalent Insulin Receptor Activation Using Insulin–DNA Origami Nanostructures.” Nature Nanotechnology, 2023.
BibTeX Click to copy
@article{joel2023a,
title = {Multivalent insulin receptor activation using insulin–DNA origami nanostructures},
year = {2023},
journal = {Nature Nanotechnology},
author = {Spratt, Joel and Dias, José M. and Kolonelou, Christina and Kiriako, Georges and Engström, Enya and Petrova, Ekaterina and Karampelias, Christos and Cervenka, I. and Papanicolaou, Natali and Lentini, Antonio and Reinius, B. and Andersson, Olov and Ambrosetti, Elena and Ruas, Jorge L. and Teixeira, Ana I.}
}
Insulin binds the insulin receptor (IR) and regulates anabolic processes in target tissues. Impaired IR signalling is associated with multiple diseases, including diabetes, cancer and neurodegenerative disorders. IRs have been reported to form nanoclusters at the cell membrane in several cell types, even in the absence of insulin binding. Here we exploit the nanoscale spatial organization of the IR to achieve controlled multivalent receptor activation. To control insulin nanoscale spatial organization and valency, we developed rod-like insulin–DNA origami nanostructures carrying different numbers of insulin molecules with defined spacings. Increasing the insulin valency per nanostructure markedly extended the residence time of insulin–DNA origami nanostructures at the receptors. Both insulin valency and spacing affected the levels of IR activation in adipocytes. Moreover, the multivalent insulin design associated with the highest levels of IR activation also induced insulin-mediated transcriptional responses more effectively than the corresponding monovalent insulin nanostructures. In an in vivo zebrafish model of diabetes, treatment with multivalent—but not monovalent—insulin nanostructures elicited a reduction in glucose levels. Our results show that the control of insulin multivalency and spatial organization with nanoscale precision modulates the IR responses, independent of the insulin concentration. Therefore, we propose insulin nanoscale organization as a design parameter in developing new insulin therapies. DNA-origami-based insulin assembly into well-defined nanoclusters reveals that insulin valency and spatial organization modulate insulin receptor activation and downstream responses independent of ligand concentration.